South Korea Epilepsy Market Size, Share, and COVID-19 Impact Analysis, By Condition (Drug Resistant/Intractable Epilepsy, and Others), By Diagnosis and Treatment (Diagnosis and Treatment), and South Korea Epilepsy Market Insights, Industry Trend, Forecasts to 2035

South Korea Epilepsy Market Insights Forecasts to 2035

• The South Korea Epilepsy Market Size was Estimated at USD 11.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 9.38% from 2025 to 2035
• The South Korea Epilepsy Market Size is Expected to Reach USD 29.5 Million by 2035

According to a research report published by Spherical Insights & Consulting, The South Korea Epilepsy Market Size is anticipated to reach USD 29.5 Million by 2035, growing at a CAGR of 9.38% from 2025 to 2035. Rising rates of epilepsy, government awareness campaigns, improvements in antiepileptic medications, the growth of telemedicine, and individualized treatment plans particularly for children and drug-resistant cases are all contributing factors to this increase.

Market Overview

The South Korea Epilepsy Market encompasses the diagnosis, treatment, and management of epilepsy ecosystem, including medications, medical equipment, and healthcare services, is covered by the South Korean epilepsy market. It addresses both drug-resistant and general epilepsy cases and involves stakeholders like hospitals, clinics, diagnostic centers, and pharmaceutical companies. Government awareness campaigns, technological developments, and an increasing emphasis on pediatric and personalized care all influence the market. Additionally, Improvements in medical care and greater awareness of neurological conditions are driving significant changes in the South Korean epilepsy market. One of the key factors driving the market is the increased awareness of epilepsy and the challenges it presents. The South Korean government's efforts to de-stigmatize epilepsy and raise public awareness of the condition have led to improved diagnosis and treatment rates. Furthermore, the development of new antiepileptic drugs (AEDs) has accelerated.

Report Coverage

This research report categorizes the market for the South Korea epilepsy market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea epilepsy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea epilepsy market. thanks to robust research from academic institutions and local pharmaceutical companies. There are opportunities to research pediatric epilepsy care as more kids are given epilepsy diagnoses and require specialized medical care.

Driving Factors

In South Korea, awareness and education campaigns about epilepsy are becoming more and more important. Numerous groups, such as the Korean Epilepsy Society, are leading campaigns to inform the public and medical professionals about the signs and symptoms of epilepsy, available treatments, and effective management techniques. The Health Insurance Review and Assessment Service (HIRA) reports that over the previous five years, there has been a 20% increase in diagnoses as a result of increased awareness. As a result, this increase in awareness has a direct impact on treatment accessibility and enhances patient outcomes, fostering an environment that is more conducive to the growth of the South Korean epilepsy market. More customers are likely to seek treatment as a result of improved education initiatives, which will increase the patient base and foster market growth.

Restraining Factors

Many South Koreans still have misconceptions about epilepsy, which contributes to social stigma that prevents candid conversations and prompt medical care. Patients experience delayed diagnosis, poor treatment adherence, and emotional distress as a result of this ignorance, particularly in rural areas where access to specialized care and accurate information is more restricted.

Market Segmentation

The South Korea epilepsy market share is classified into condition, and diagnosis and treatment.

• The drug-resistant/intractable epilepsy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea epilepsy market is segmented by condition into drug-resistant/intractable epilepsy and others. Among these, the drug-resistant/intractable epilepsy segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The demand for cutting-edge treatments like cenobamate is being driven by the rising number of patients who do not respond to conventional anti-seizure drugs. Improved diagnostics, targeted treatment innovations, and increased awareness all contribute to the segment's growth.

• The treatment segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period

The South Korea epilepsy market is segmented by diagnosis and treatment into diagnosis and treatment. Among these, the treatment segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The treatment side concentrates on advanced surgical options and pharmaceutical advancements, such as new antiepileptic medications, which are crucial for effectively managing seizures. Technological developments and growing research funding are driving this industry, emphasizing the value of individualized treatment programs.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea epilepsy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Dong-A ST
• Samsung Medical Center
• Hanyang University Hospital
• SK Biopharmaceuticals
• Others

Recent Developments:

• In February 2025, Dong-A ST had announced that it had submitted a marketing authorization application for Cenobamate to the Ministry of Food and Drug Safety (MFDS). The product was to be marketed under the name ‘Xcopri.’

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea Epilepsy Market based on the below-mentioned segments:

South Korea Epilepsy Market, By Condition

• Drug Resistant/Intractable Epilepsy
• Others

South Korea Epilepsy Market, By Diagnosis and Treatment

• Diagnosis
• Treatment